U.S. stocks closed higher Friday, booking weekly gains with support from data confirming an economic recovery from the coronavirus pandemic, despite inflation running at its highest annual rate in about 13 years.
Pfizer, Inc. (NYSE: PFE) and
Myovant Sciences (NYSE: MYOV) announced FDA approval for once-daily Myfembree, relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
The companies said they will jointly commercialize Myfembree in the U.S. Myfembree is expected to be available in June.
Pfizer shares edged down 0.15% to $38.86 in after-hours trading and Myovant receded 0.34% to $23.60.
Zosano Announces Publication Of Positive Results From Long-Term Use Of Migraine Drug
Zosano Pharma Corporation (NASDAQ: ZSAN) announced that an article titled, Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine was published in the Journal of Headache and Pain
Monday, May 24, 2021
Introduction
In a post-grant review (PGR), the Patent Trial and Appeal Board (“the Board”) reviews the patentability of one or more patent claims on any ground that could be raised under 35 U.S.C. § 282(b)(2) or (3), including, e.g., obviousness. The PGR process starts when a third party files a petition within 9 months of the grant of the challenged patent or issuance of a reissue patent. Under 35 U.S.C. § 324(a), the Board may institute a PGR if the petitioner shows it is more likely than not that at least one challenged claim is unpatentable.
A PGR petition may only be instituted if the petitioner meets its burden to show, “in writing and with particularity, each claim challenged, the grounds on which the challenge to each claim is based, and the evidence that supports the grounds for the challenge to each claim.” 35 U.S.C. § 322(a)(3);
Company s 52-week low was at $4.33
Price action over last quarter: down 1.87%
Company Overview
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eight product candidates in various stages of development.
Related Articles (ETON)